HTG, OvaGene Reach Assay Development Deal for Gynecologic Cancers | GenomeWeb

NEW YORK (GenomeWeb News) – HTG Molecular Diagnostics and OvaGene Oncology today announced a manufacturing supply agreement for the design and development of gene expression assays for gynecologic cancers on HTG's platform.

Under the terms of the deal, OvaGene will develop the assays on the HTG Edge System, an automated gene expression platform that delivers multiplexed results on lysed samples in less than one day. HTG launched the platform in 2013 with a portfolio of mRNA assays based on the company's proprietary nuclease protection chemistry.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.